Bioventix (BVXP) AI Stock Analysis

• Market Cap: £72.36M
• Dividend Yield: 8.33%
• Average Volume (3M): 7.85K
• Price to Earnings (P/E): 9.4
• Beta (1Y): 0.31
• Revenue Growth: -3.61%
• EPS Growth: -6.35%
• Country: UK
• Employees: 17
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.72
• Shares Outstanding: 5,224,860
• 10 Day Avg. Volume: 9,152
• 30 Day Avg. Volume: 7,851
• PEG Ratio: -2.93
• Price to Book (P/B): 12.43
• Price to Sales (P/S): 10.95
• P/FCF Ratio: 20.47
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 1.36
• Revenue Forecast (FY): £12.50M

• Rating: 75 Outperform
• Price Target: 1,558.00 p ▼(-13.44% Downside)
• Action: Reiterated Date: 12/30/25
• Date: Action: Reiterated 12/30/25

The score is driven primarily by very strong financial quality (high profitability, strong cash conversion, and no debt). This is tempered by weak technicals (price below key moving averages with negative MACD) and signs of slowing operating momentum in 2025. Valuation and dividend yield are supportive, while corporate updates are mixed (insider buying versus revenue/profit pressure).

Positive Factors

High profitability and margins

Bioventix has persistently very high gross, operating and net margins (roughly 58–70%), which supports sustained free cash generation and return on equity. Elite margins create durable earnings power, allowing the company to fund operations and return capital even if growth softens.

Negative Factors

Recent revenue and FCF decline

The company experienced a measurable slowdown in 2025 with declines in revenue and free cash flow versus 2024. A sustained top-line and cash trend reversal could pressure reinvestment capacity, dividend coverage, and the ability to fund new R&D or commercial placements over coming quarters.

Bioventix Business Overview & Revenue Model

Company Description

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious dise...

Read more

Bioventix PLC creates, manufactures, and supplies sheep monoclonal antibodies (SMAs) for diagnostic applications worldwide. The company offers a portfolio of purified SMAs for thyroid, vitamin D, cardiac, drugs of abuse, fertility, infectious dise...

How the Company Makes Money

Bioventix primarily makes money by licensing and supplying proprietary monoclonal antibody reagents to in-vitro diagnostics (IVD) and immunoassay platform manufacturers. Revenue is typically generated in two main ways: (1) upfront/initial payments...

Read more

Bioventix primarily makes money by licensing and supplying proprietary monoclonal antibody reagents to in-vitro diagnostics (IVD) and immunoassay platform manufacturers. Revenue is typically generated in two main ways: (1) upfront/initial payments...

Bioventix Financial Statement Overview

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	13.12M	13.61M	12.82M	11.72M	10.93M
Gross Profit	11.92M	12.68M	11.86M	10.87M	9.98M
EBITDA	10.17M	10.74M	10.20M	9.42M	8.22M
Net Income	7.58M	8.10M	8.37M	7.67M	6.73M
Balance Sheet
Total Assets	12.86M	13.73M	13.28M	13.12M	12.91M
Cash, Cash Equivalents and Short-Term Investments	5.08M	6.00M	5.72M	6.13M	6.49M
Total Debt	0.00	0.00	0.00	0.00	0.00
Total Liabilities	1.31M	1.73M	1.22M	1.30M	1.09M
Stockholders Equity	11.55M	12.00M	12.06M	11.82M	11.82M
Cash Flow
Free Cash Flow	7.01M	8.33M	7.89M	7.55M	6.11M
Operating Cash Flow	7.03M	8.34M	7.90M	7.56M	6.37M
Investing Cash Flow	173.16K	186.06K	90.51K	-11.76K	-259.83K
Financing Cash Flow	-8.12M	-8.25M	-8.30M	-7.92M	-7.69M

Bioventix Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1800.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:BVXP, the sentiment is Negative. The current price of 1800 is above the 20-day moving average (MA) of 1471.00, above the 50-day MA of 1631.20, and below the 200-day MA of 2093.65, indicating a bearish trend. The MACD of -65.60 indicates Negative momentum. The RSI at 31.79 is Neutral, neither overbought nor oversold. The STOCH value of 41.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for GB:BVXP.

Bioventix Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BVXP	75 Outperform	£72.36M	9.42	66.44%	8.33%	-3.61%	-6.35%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
FAB	44 Neutral	£16.57M	-9.67	-210.32%	―	-11.43%	23.40%
AVCT	42 Neutral	£299.62M	-1.74	-361.23%	―	―	―
4BB	41 Neutral	£78.97M	-4.89	-63.53%	―	198.49%	-26.66%
OBD	40 Underperform	£8.58M	-0.59	-316.67%	―	72.17%	79.03%
APTA	40 Underperform	£16.86M	-6.19	-213.66%	―	39.88%	81.33%

Bioventix Corporate Events